1. EatonJE, TalwalkarJA, LazaridisKN, et al.Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology2013;145:521. CrossRef

2. BambhaK, KimWR, TalwalkarJ, et al.Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology2003;125:1364. CrossRef

3. MolodeckyNA, KareemiH, ParabR, et al.Incidence of primary sclerosing cholangitis: a systematic review and meta‐analysis. Hepatology2011;53:1590. CrossRef

4. FarrantJM, HayllarKM, WilkinsonML, et al.Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology1991;100:1710.

5. SchrumpfE, AbdelnoorM, FausaO, et al.Risk factors in primary sclerosing cholangitis. J Hepatol1994;21:1061. CrossRef

6. BroomeU, OlssonR, LoofL, et al.Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut1996;38:610. CrossRef

7. OkolicsanyiL, FabrisL, ViaggiS, et al.Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol1996;8:685.

8. OlssonR, DanielssonA, JarnerotG, et al.Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology1991;100:1319.

9. RasmussenHH, FallingborgJF, MortensenPB, et al.Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol1997;32:604. CrossRef

10. TakikawaH, ManabeT. Primary sclerosing cholangitis in Japan – analysis of 192 cases. J Gastroenterol1997;32:134. CrossRef

11. EscorsellA, ParesA, RodesJ, et al.Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol1994;21:787. CrossRef

12. BobergKM, AadlandE, JahnsenJ, et al.Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol1998;33:99. CrossRef

13. HarriesAD, BairdA, RhodesJ. Non‐smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed)1982;284:706. CrossRef

14. LoftusEVJr, SandbornWJ, TremaineWJ, et al.Primary sclerosing cholangitis is associated with nonsmoking: a case‐control study. Gastroenterology1996;110:1496. CrossRef

15. KarlsenTH, FrankeA, MelumE, et al.Genome‐wide association analysis in primary sclerosing cholangitis. Gastroenterology2010;138:1102. CrossRef

16. MelumE, FrankeA, SchrammC, et al.Genome‐wide association analysis in primary sclerosing cholangitis identifies two non‐HLA susceptibility loci. Nat Genet2011;43:17. CrossRef

17. KarlsenTH, BobergKM, OlssonM, et al.Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol2007;46:899. CrossRef

18. TraherneJA. Human MHC architecture and evolution: implications for disease association studies. Int J Immunogenet2008;35:179. CrossRef

19. CoquetJM, KyparissoudisK, PellicciDG, et al.IL‐21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol2007;178:2827. CrossRef

20. Parrish‐NovakJ, DillonSR, NelsonA, et al.Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature2000;408:57. CrossRef

21. SpolskiR, LeonardWJ. Interleukin‐21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol2008;26:57. CrossRef

22. KornT, BettelliE, GaoW, et al.IL‐21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature2007;448:484. CrossRef

23. NarumiS, RobertsJP, EmondJC, et al.Liver transplantation for sclerosing cholangitis. Hepatology1995;22:451. CrossRef

24. ZhouL, IvanovII, SpolskiR, et al.IL‐6 programs T(H)‐17 cell differentiation by promoting sequential engagement of the IL‐21 and IL‐23 pathways. Nat Immunol2007;8:967. CrossRef

25. StrasserA. The role of BH3‐only proteins in the immune system. Nat Rev Immunol2005;5:189. CrossRef

26. SatsangiJ, ParkesM, LouisE, et al.Two stage genome‐wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet1996;14:199. CrossRef

27. GoyetteP, LefebvreC, NgA, et al.Gene‐centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol2008;1:131. CrossRef

28. RaelsonJV, LittleRD, RuetherA, et al.Genome‐wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc Natl Acad Sci U S A2007;104:14747. CrossRef

29. YoshimuraT, YuhkiN, WangMH, et al.Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J Biol Chem1993;268:15461.

30. LeiXG, ChengWH. New roles for an old selenoenzyme: evidence from glutathione peroxidase‐1 null and overexpressing mice. J Nutr2005;135:2295.

31. EsworthyRS, ArandaR, MartinMG, et al.Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol2001;281:G848.

32. EsworthyRS, BinderSW, DoroshowJH, et al.Microflora trigger colitis in mice deficient in selenium‐dependent glutathione peroxidase and induce Gpx2 gene expression. Biol Chem2003;384:597. CrossRef

33. HovJR, KeitelV, LaerdahlJK, et al.Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS ONE2010;5:e12403. CrossRef

34. KawamataY, FujiiR, HosoyaM, et al.A G protein‐coupled receptor responsive to bile acids. J Biol Chem2003;278:9435. CrossRef

35. KeitelV, DonnerM, WinandyS, et al.Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun2008;372:78. CrossRef

36. FiorucciS, MencarelliA, PalladinoG, et al.Bile‐acid‐activated receptors: targeting TGR5 and farnesoid‐X‐receptor in lipid and glucose disorders. Trends Pharmacol Sci2009;30:570. CrossRef

37. SaarinenS, OlerupO, BroomeU. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol2000;95:3195. CrossRef

38. SchrumpfE, FausaO, ForreO, et al.HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol1982;17:187. CrossRef

39. LindorKD, WiesnerRH, LaRussoNF, et al.Enhanced autoreactivity of T‐lymphocytes in primary sclerosing cholangitis. Hepatology1987;7:884. CrossRef

40. BoX, BroomeU, RembergerM, et al.Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut2001;49:131. CrossRef

41. LindorKD, WiesnerRH, KatzmannJA, et al.Lymphocyte subsets in primary sclerosing cholangitis. Dig Dis Sci1987;32:720. CrossRef

42. BodenheimerHCJr, LaRussoNF, ThayerWRJr, et al.Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology1983;3:150. CrossRef

43. MandalA, DasguptaA, JeffersL, et al.Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology1994;106:185.

44. DuerrRH, TarganSR, LandersCJ, et al.Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology1991;100:1385.

45. LoSK, FlemingKA, ChapmanRW. A 2‐year follow‐up study of anti‐neutrophil antibody in primary sclerosing cholangitis: relationship to clinical activity, liver biochemistry and ursodeoxycholic acid treatment. J Hepatol1994;21:974. CrossRef

46. MulderAH, HorstG, HaagsmaEB, et al.Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology1993;17:411. CrossRef

47. TerjungB, SpenglerU. Atypical p‐ANCA in PSC and AIH: a hint toward a “leaky gut. Clin Rev Allergy Immunol2009;36:40. CrossRef

48. BansiDS, FlemingKA, ChapmanRW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut1996;38:384. CrossRef

49. RoozendaalC, Van Milligen de WitAW, HaagsmaEB, et al.Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med1998;105:393. CrossRef

50. AnguloP, LindorKD. Primary sclerosing cholangitis. Hepatology1999;30:325. CrossRef

51. CangemiJR, WiesnerRH, BeaverSJ, et al.Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology1989;96:790.

52. EksteenB, GrantAJ, MilesA, et al.Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut‐homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med2004;200:1511. CrossRef

53. BjornssonE, CederborgA, AkvistA, et al.Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol2005;40:1090. CrossRef

54. MehalWZ, HattersleyAT, ChapmanRW, et al.A survey of cytomegalovirus (CMV) DNA in primary sclerosing cholangitis (PSC) liver tissues using a sensitive polymerase chain reaction (PCR) based assay. J Hepatol1992;15:396. CrossRef

55. WashingtonK, ClavienPA, KillenbergP. Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis. Hum Pathol1997;28:791. CrossRef

56. LeeYM, KaplanMM. Primary sclerosing cholangitis. N Engl J Med1995;332:924. CrossRef

57. BergquistA, SaidK, BroomeU. Changes over a 20‐year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol2007;42:88. CrossRef

58. HelzbergJH, PetersenJM, BoyerJL. Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology1987;92:1869.

59. AadlandE, SchrumpfE, FausaO, et al.Primary sclerosing cholangitis: a long‐term follow‐up study. Scand J Gastroenterol1987;22:655. CrossRef

60. WiesnerRH, GrambschPM, DicksonER, et al.Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology1989;10:430. CrossRef

61. BobergKM, FausaO, HaalandT, et al.Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology1996;23:1369. CrossRef

62. SeiboldF, WeberP, KleinR, et al.Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut1992;33:657. CrossRef

63. AnguloP, PeterJB, GershwinME, et al.Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol2000;32:182. CrossRef

64. MacCartyRL, LaRussoNF, WiesnerRH, et al.Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology1983;149:39. CrossRef

65. TeefeySA, BaronRL, RohrmannCA, et al.Sclerosing cholangitis: CT findings. Radiology1988;169:635. CrossRef

66. OhtomoK, BaronRL, DoddGD3rd, et al.Confluent hepatic fibrosis in advanced cirrhosis: appearance at CT. Radiology1993;188:31. CrossRef

67. RevelonG, RashidA, KawamotoS, et al.Primary sclerosing cholangitis: MR imaging findings with pathologic correlation. Am J Roentgenol1999;173:1037. CrossRef

68. MaetaniY, ItohK, WatanabeC, et al.MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. Am J Roentgenol2001;176:1499. CrossRef

69. JonasE, NaslundE, FreedmanJ, et al.Measurement of parenchymal function and bile duct flow in primary sclerosing cholangitis using dynamic 99mTc‐HIDA SPECT. J Gastroenterol Hepatol2006;21:674. CrossRef

70. MesenasS, VuC, DoigL, et al.Duodenal EUS to identify thickening of the extrahepatic biliary tree wall in primary sclerosing cholangitis. Gastrointest Endosc2006;63:403. CrossRef

71. TischendorfJJ, KrugerM, TrautweinC, et al.Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy2006;38:665. CrossRef

72. AwadallahNS, ChenYK, PirakaC, et al.Is there a role for cholangioscopy in patients with primary sclerosing cholangitis?Am J Gastroenterol2006;101:284. CrossRef

73. LudwigJ. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol1989;13:43.

74. OlssonR, HagerstrandI, BroomeU, et al.Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol1995;48:933. CrossRef

75. AnguloP, LindorKD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Dis1999;3:529. CrossRef

76. KimWR, LudwigJ, LindorKD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol2000;95:1130. CrossRef

77. McFarlaneIG. Autoimmune liver diseases. Scand J Clin Lab Invest Suppl2001;235:53.

78. WilschanskiM, ChaitP, WadeJA, et al.Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology1995;22:1415.

79. KayaM, AnguloP, LindorKD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol2000;33:537. CrossRef

80. van BuurenHR, van HoogstratenHJE, TerkivatanT, et al.High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol2000;33:543. CrossRef

81. DeshpandeV, ChicanoS, FinkelbergD, et al.Autoimmune pancreatitis: a systemic immune complex mediated disease. Am J Surg Pathol2006;30:1537. CrossRef

82. NishinoT, TokiF, OyamaH, et al.Biliary tract involvement in autoimmune pancreatitis. Pancreas2005;30:76.

83. SteinhartAH, SimonsM, StoneR, et al.Multiple hepatic abscesses: cholangiographic changes simulating sclerosing cholangitis and resolution after percutaneous drainage. Am J Gastroenterol1990;85:306.

84. LamSK, WongKP, ChanPK, et al.Recurrent pyogenic cholangitis: a study by endoscopic retrograde cholangiography. Gastroenterology1978;74:1196.

85. PatelSA, BorgesMC, BattMD, et al.Trichosporon cholangitis associated with hyperbilirubinemia, and findings suggesting primary sclerosing cholangitis on endoscopic retrograde cholangiopancreatography. Am J Gastroenterol1990;85:84.

86. ViteriAL, GreeneJFJr. Bile duct abnormalities in the acquired immune deficiency syndrome. Gastroenterology1987;92:2014.

87. SavaderSJ, BenenatiJF, VenbruxAC, et al.Choledochal cysts: classification and cholangiographic appearance. Am J Roentgenol1991;156:327. CrossRef

88. O'BrienS, KeoganM, CaseyM, et al.Biliary complications of cystic fibrosis. Gut1992;33:387. CrossRef

89. TeradaT, NakanumaY. Intrahepatic cholangiographic appearance simulating primary sclerosing cholangitis in several hepatobiliary diseases: a postmortem cholangiographic and histopathological study in 154 livers at autopsy. Hepatology1995;22:75. CrossRef

90. GrahamSM, BarwickK, CahowCE, et al.Cholangitis glandularis proliferans. A histologic variant of primary sclerosing cholangitis with distinctive clinical and pathological features. J Clin Gastroenterol1988;10:579. CrossRef

91. GrauerL, PadillaVM3rd, BouzaL, et al.Eosinophilic sclerosing cholangitis associated with hypereosinophilic syndrome. Am J Gastroenterol1993;88:1764.

92. YounossiZM, KiwiML, BoparaiN, et al.Cholestatic liver diseases and health‐related quality of life. Am J Gastroenterol2000;95:497. CrossRef

93. HerndonJHJr. Pathophysiology of pruritus associated with elevated bile acid levels in serum. Arch Intern Med1972;130:632. CrossRef

94. JonesEA, BergasaNV. The pruritus of cholestasis and the opioid system. JAMA1992;268:3359. CrossRef

95. PolterDE, GruhlV, EigenbrodtEH, et al.Beneficial effect of cholestyramine in sclerosing cholangitis. Gastroenterology1980;79:326.

96. BloomerJR, BoyerJL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med1975;82:310. CrossRef

97. ChazouilleresO, PouponR, CapronJP, et al.Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol1990;11:120. CrossRef

98. PrinceMI, BurtAD, JonesDE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut2002;50:436. CrossRef

99. TabibianN. Rifampin as antipruritic agent in primary sclerosing cholangitis. Am J Gastroenterol1989;84:340.

100. WolfhagenFH, SternieriE, HopWC, et al.Oral naltrexone treatment for cholestatic pruritus: a double‐blind, placebo‐controlled study. Gastroenterology1997;113:1264. CrossRef

101. LauterburgBH, PinedaAA, DicksonER, et al.Plasmaperfusion for the treatment of intractable pruritus of cholestasis. Mayo Clin Proc1978;53:403.

102. GomezRL, GriffinJWJr, SquiresJE. Prolonged relief of intractable pruritus in primary sclerosing cholangitis by plasmapheresis. J Clin Gastroenterol1986;8:301. CrossRef

103. StellonAJ, WebbA, CompstonJ, et al.Lack of osteomalacia in chronic cholestatic liver disease. Bone1986;7:181. CrossRef

104. JanesCH, DicksonER, OkazakiR, et al.Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest1995;95:2581. CrossRef

105. GuichelaarMM, MalinchocM, SibongaJ, et al.Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology2002;36:895. CrossRef

106. JorgensenRA, LindorKD, SartinJS, et al.Serum lipid and fat‐soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol1995;20:215. CrossRef

107. HayJE, MalinchocM, DicksonER. A controlled trial of calcitonin therapy for the prevention of post‐liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol2001;34:292. CrossRef

108. AnguloP, TherneauTM, JorgensenA, et al.Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol1998;29:729. CrossRef

109. HayJE, LindorKD, WiesnerRH, et al.The metabolic bone disease of primary sclerosing cholangitis. Hepatology1991;14:257. CrossRef

110. GuichelaarMM, KendallR, MalinchocM, et al.Bone mineral density before and after OLT: long‐term follow‐up and predictive factors. Liver Transpl2006;12:1390. CrossRef

111. CampbellMS, LichtensteinGR, RhimAD, et al.Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int2005;25:311. CrossRef

112. HayJE, WiesnerRH, ShorterRG, et al.Primary sclerosing cholangitis and celiac disease. A novel association. Ann Intern Med1988;109:713. CrossRef

113. VenturiniI, CosenzaR, MiglioliL, et al.Adult celiac disease and primary sclerosing cholangitis: two case reports. Hepatogastroenterology1998;45:2344.

114. EpsteinO, ChapmanRW, Lake‐BakaarG, et al.The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis. Gastroenterology1982;83:1177.

115. MontefuscoPP, GeissAC, BronzoRL, et al.Sclerosing cholangitis, chronic pancreatitis, and Sjogren's syndrome: a syndrome complex. Am J Surg1984;147:822. CrossRef

116. MunozSJ, HeubiJE, BalistreriWF, et al.Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid‐soluble vitamins. Hepatology1989;9:525. CrossRef

117. DoddGD3rd, NiedzwieckiGA, CampbellWL, et al.Bile duct calculi in patients with primary sclerosing cholangitis. Radiology1997;203:443. CrossRef

118. LeeJG, SchutzSM, EnglandRE, et al.Endoscopic therapy of sclerosing cholangitis. Hepatology1995;21:661.

119. PittHA, VenbruxAC, ColemanJ, et al.Intrahepatic stones. The transhepatic team approach. Ann Surg1994;219:527. CrossRef

120. MartinFM, RossiRL, NugentFW, et al.Surgical aspects of sclerosing cholangitis. Results in 178 patients. Ann Surg1990;212:551. CrossRef

121. MayGR, BenderCE, LaRussoNF, et al.Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis. Am J Roentgenol1985;145:1061. CrossRef

122. PonsioenCY, LamK, van Milligen de WitAW, et al.Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol1999;94:2403. CrossRef

123. van Milligen de WitAW, RauwsEA, van BrachtJ, et al.Lack of complications following short‐term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc1997;46:344. CrossRef

124. KayaM, PetersenBT, AnguloP, et al.Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol2001;96:1059. CrossRef

125. PonsioenCY, VrouenraetsSM, van Milligen de WitAW, et al.Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy1999;31:305. CrossRef

126. BurakK, AnguloP, PashaTM, et al.Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol2004;99:523. CrossRef

127. Abu‐ElmagdKM, MalinchocM, DicksonER, et al.Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet1993;177:335.

128. GossJA, ShackletonCR, FarmerDG, et al.Orthotopic liver transplantation for primary sclerosing cholangitis. A 12‐year single center experience. Ann Surg1997;225:472. CrossRef

129. MuiesanP, ShanmugamRP, DevlinJ, et al.Orthotopic liver transplantation for primary sclerosing cholangitis. Transplant Proc1994;26:3574.

130. StrasserS, SheilAG, GallagherND, et al.Liver transplantation for primary sclerosing cholangitis versus primary biliary cirrhosis: a comparison of complications and outcome. J Gastroenterol Hepatol1993;8:238. CrossRef

131. BroomeU, LofbergR, VeressB, et al.Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology1995;22:1404.

132. AhrendtSA, PittHA, NakeebA, et al.Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Surg1999;3:357. CrossRef

133. ShaibYH, El‐SeragHB, DavilaJA, et al.Risk factors of intrahepatic cholangiocarcinoma in the United States: a case‐control study. Gastroenterology2005;128:620. CrossRef

134. BergquistA, GlaumannH, PerssonB, et al.Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case‐control study. Hepatology1998;27:311. CrossRef

135. ChalasaniN, BaluyutA, IsmailA, et al.Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case‐control study. Hepatology2000;31:7. CrossRef

136. BobergKM, SchrumpfE, BergquistA, et al.Cholangiocarcinoma in primary sclerosing cholangitis: K‐ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol2000;32:374. CrossRef

137. KubickaS, KuhnelF, FlemmingP, et al.K‐ras mutations in the bile of patients with primary sclerosing cholangitis. Gut2001;48:403. CrossRef

138. RizziPM, RyderSD, PortmannB, et al.p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut1996;38:265. CrossRef

139. AhrendtSA, EisenbergerCF, YipL, et al.Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis‐associated cholangiocarcinoma. J Surg Res1999;84:88. CrossRef

140. NashanB, SchlittHJ, TuschG, et al.Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. Hepatology1996;23:1105. CrossRef

141. CampbellWL, FerrisJV, HolbertBL, et al.Biliary tract carcinoma complicating primary sclerosing cholangitis: evaluation with CT, cholangiography, US, and MR imaging. Radiology1998;207:41. CrossRef

142. PrytzH, KeidingS, BjornssonE, et al.Dynamic FDG‐PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology2006;44:1572. CrossRef

143. PatelAH, HarnoisDM, KleeGG, et al.The utility of CA 19‐9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol2000;95:204. CrossRef

144. RabinovitzM, ZajkoAB, HassaneinT, et al.Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures. Hepatology1990;12:747. CrossRef

145. BergquistA, TribukaitB, GlaumannH, et al.Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis?J Hepatol2000;33:873. CrossRef

146. Moreno LunaLE, KippB, HallingKC, et al.Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology2006;131:1064. CrossRef

147. ChapmanR, FeveryJ, KallooA, et al.Diagnosis and management of primary sclerosing cholangitis. Hepatology2010;51:660. CrossRef

148. AhrendtSA, PittHA, KallooAN, et al.Primary sclerosing cholangitis: resect, dilate, or transplant?Ann Surg1998;227:412. CrossRef

149. KayaM, de GroenPC, AnguloP, et al.Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterol2001;96:1164. CrossRef

150. Darwish MuradS, KimWR, HarnoisDM, et al.Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology2012;143:88. CrossRef

151. SakaiM, EgawaN, SakamakiH, et al.Primary sclerosing cholangitis complicated with idiopathic thrombocytopenic purpura. Intern Med2001;40:1209. CrossRef

152. BrentnallTA, HaggittRC, RabinovitchPS, et al.Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology1996;110:331. CrossRef

153. KornfeldD, EkbomA, IhreT. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut1997;41:522. CrossRef

154. LindbergBU, BroomeU, PerssonB. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20‐year surveillance study. Dis Colon Rectum2001;44:77. CrossRef

155. LoftusEVJr, AguilarHI, SandbornWJ, et al.Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology1998;27:685. CrossRef

156. NuakoKW, AhlquistDA, SandbornWJ, et al.Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case‐control study. Cancer1998;82:822. CrossRef

157. SoetiknoRM, LinOS, HeidenreichPA, et al.Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta‐analysis. Gastrointest Endosc2002;56:48. CrossRef

158. VeraA, GunsonBK, UssatoffV, et al.Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation2003;75:1983. CrossRef

159. TungBY, EmondMJ, HaggittRC, et al.Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med2001;134:89. CrossRef

160. PardiDS, LoftusEVJr, KremersWK, et al.Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology2003;124:889. CrossRef

161. BledayR, LeeE, JessurunJ, et al.Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum1993;36:908. CrossRef

162. HigashiH, YanagaK, MarshJW, et al.Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Hepatology1990;11:477. CrossRef

163. JanczewskaI, OlssonR, HultcrantzR, et al.Pregnancy in patients with primary sclerosing cholangitis. Liver1996;16:326. CrossRef

164. van den HazelSJ, WolfhagenEH, van BuurenHR, et al.Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy2000;32:779. CrossRef

165. CraigDA, MacCartyRL, WiesnerRH, et al.Primary sclerosing cholangitis: value of cholangiography in determining the prognosis. Am J Roentgenol1991;157:959. CrossRef

166. StiehlA, RudolphG, Kloters‐PlachkyP, et al.Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol2002;36:151. CrossRef

167. AllisonMC, BurroughsAK, NooneP, et al.Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. J Hepatol1986;3:118. CrossRef

168. WagnerS, GebelM, MeierP, et al.Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy1996;28:546. CrossRef

169. StiehlA, RudolphG, SauerP, et al.Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8‐year prospective study. J Hepatol1997;26:560. CrossRef

170. SeabergEC, BelleSH, BeringerKC, et al.Liver transplantation in the United States from 1987–1998: updated results from the Pitt‐UNOS Liver Transplant Registry. Clin Transpl1998;17.

171. PapatheodoridisGV, HamiltonM, MistryPK, et al.Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut1998;43:639. CrossRef

172. ZinsBJ, SandbornWJ, PennaCR, et al.Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch‐anal anastomosis. Am J Gastroenterol1995;90:2177.

173. BrandsaeterB, SchrumpfE, BentdalO, et al.Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl2005;11:1361. CrossRef

174. GautamM, CheruvattathR, BalanV. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl2006;12:1813. CrossRef

175. GraziadeiIW, WiesnerRH, BattsKP, et al.Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology1999;29:1050. CrossRef

176. HarrisonRF, DaviesMH, NeubergerJM, et al.Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis?Hepatology1994;20:356. CrossRef

177. KugelmasM, SpiegelmanP, OsgoodMJ, et al.Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl2003;9:727. CrossRef

178. HeneghanMA, Tuttle‐NewhallJE, SuhockiPV, et al.De‐novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant. Am J Transplant2003;3:634. CrossRef

179. AnguloP, Maor‐KendlerY, LindorKD. Small‐duct primary sclerosing cholangitis: a long‐term follow‐up study. Hepatology2002;35:1494. CrossRef

180. BjornssonE, BobergKM, CullenS, et al.Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut2002;51:731. CrossRef

181. DicksonER, MurtaughPA, WiesnerRH, et al.Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology1992;103:1893.

182. KimWR, TherneauTM, WiesnerRH, et al.A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc2000;75:688. CrossRef

183. KimWR, PoteruchaJJ, WiesnerRH, et al.The relative role of the Child‐Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology1999;29:1643. CrossRef

184. LaRussoNF, ShneiderBL, BlackD, et al.Primary sclerosing cholangitis: summary of a workshop. Hepatology2006;44:746. CrossRef

185. NeubergerJ, GunsonB, KomolmitP, et al.Pretransplant prediction of prognosis after liver transplantation in primary sclerosing cholangitis using a Cox regression model. Hepatology1999;29:1375. CrossRef

186. KimWR, TherneauTM, DicksonER, et al.Preoperative predictors of resource utilization in liver transplantation. Clin Transpl1995;315.

187. RicciP, TherneauTM, MalinchocM, et al.A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology1997;25:672. CrossRef

188. TalwalkarJA, SeabergE, KimWR, et al.Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and Child‐Pugh score. National Institutes of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database Group. Liver Transpl2000;6:753. CrossRef

189. WeeA, LudwigJ. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?Ann Intern Med1985;102:581. CrossRef

190. BroomeU, GlaumannH, LindstomE, et al.Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol2002;36:586. CrossRef

191. AlvarezF, BergPA, BianchiFB, et al.International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol1999;31:929. CrossRef

192. FloreaniA, RizzottoER, FerraraF, et al.Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol2005;100:1516. CrossRef

193. LudwigJ. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc1998;73:285. CrossRef

194. MorenoA, CarrenoV, CanoA, et al.Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med1997;336:835. CrossRef